Rami Rahal work email
- Valid
- Valid
- Valid
Rami Rahal personal email
Rami Rahal phone numbers
Specialties: Public Biotech Investing, Small Molecule Drug Discovery, Project Leadership, Precision Oncology, Targeted Therapy, Immuno-Oncology, Genomics/ Immunogenomics, Target ID and Validation, Cell Biology, Metabolism
-
PartnerMpm BioimpactCambridge, Ma, Us
-
Senior PrincipalMpm Bioimpact Jan 2024 - PresentBoston, Massachusetts, Us
-
PrincipalMpm Bioimpact Jan 2022 - Jan 2024Boston, Massachusetts, Us
-
Senior DirectorScorpion Therapeutics Oct 2021 - Jan 2022 -
DirectorScorpion Therapeutics May 2020 - Jan 2022Leveraging the power of chemoproteomics and covalent small molecules to selectively drug 'intractable' cancer drivers. Team building.
-
Associate DirectorKsq Therapeutics, Inc. Mar 2018 - May 2020Lexington, Ma, UsSmall molecule drug discovery for in vivo validated IO targets, immunogenomics, multi-dimensional profiling of the tumor immune microenvironment, team building. -
Senior ScientistBlueprint Medicines Jul 2015 - Mar 2018Cambridge, Massachusetts, UsProject team leader of an immuno-oncology program in collaboration with a large pharmaceutical partner• Formulated and communicated the program’s strategy to the joint research committee • Facilitated project team meetings, cross-functional communication and decision making• Contributed to the design of experimental strategies to validate and understand the mechanism of action for a novel target• Guided the development of novel human and mouse immune assay systems to drive SAR and lead small-molecule selection• Integrated cellular, molecular, and genomic approaches to interrogate target biology and inform indication selection and patient identification strategiesBiology lead for BLU-667, the first highly potent and selective RET inhibitor to enter clinical development: • Conceptualized and oversaw the experimental strategy to achieve the target product profile• Leveraged cell based assays to optimize small molecule properties • Designed, organized, and evaluated proof of concept studies in disease-relevant in vivo models • Established the PK/PD-efficacy relationship• Interrogated the physiological role(s) of the target to guide interpretation of toxicology studies• Initiated and managed research collaborations with multiple CROs and academic collaborators• Contributed to the development of clinical pharmacodynamic biomarkers • Co-authored study reports and pharmacology written summary for IND applications• Authored abstracts and gave oral presentations at national and international meetings -
ScientistBlueprint Medicines Oct 2013 - Jul 2015Cambridge, Massachusetts, UsIdentification of new therapies for genetically defined cancers: - Conceived and developed a novel target identification strategy to reveal kinase targets Lead an experimental strategy to identify next-generation inhibitors of a kinase genetically deregulated in multiple cancer subtypes: - Prospectively identified mutations that promote resistance to first-generation inhibitors currently in clinical trials- Conceived, designed, and implemented cell based assays to identify highly selective inhibitors that target the wild-type kinase and the prospectively identified resistance mutants
-
Presidential FellowNovartis Institutes Of Biomedical Research Oct 2010 - Oct 2013Basel, Baselstadt, ChUsed next-generation sequencing (RNA-seq) and pharmacological profiling to identify novel therapeutic targets for mantle cell lymphoma (MCL)• Identified a pattern of mutually exclusive activation of the classical and alternative NFκB pathways in MCL lines that were sensitive or insensitive to BTK/PKC inhibition, respectively• Used RNA-seq to characterize genetic features associated with compound sensitivity and identified activating lesions in the alternative NFκB pathway in MCL lines insensitive to BTK/PKC inhibitors• Discovered similar NFκB pathway-activating mutations in in approximately 10% of MCL patients• Identified potential biomarkers of deregulated classical or alternative NFκB pathway signaling to facilitate patient stratification for clinical trials with BTK/PKC or NIK inhibitors, respectively -
Postdoctoral FellowHarvard Medical School Oct 2008 - Oct 2010Boston, Ma, UsCharacterized molecular pathways that respond to mitochondrial dysfunction using a combination of transcriptional profiling, metabolomics, and analysis of signal transduction cascades. -
Graduate StudentMit 2003 - 2008Cambridge, Ma, UsInvestigated the molecular mechanisms by which mitotic cyclin-dependent kinases coordinate genome segregation during cell division.
Rami Rahal Skills
Rami Rahal Education Details
-
Massachusetts Institute Of TechnologyGenetics -
Mcmaster UniversityBiochemistry
Frequently Asked Questions about Rami Rahal
What company does Rami Rahal work for?
Rami Rahal works for Mpm Bioimpact
What is Rami Rahal's role at the current company?
Rami Rahal's current role is Partner.
What is Rami Rahal's email address?
Rami Rahal's email address is ra****@****tis.com
What is Rami Rahal's direct phone number?
Rami Rahal's direct phone number is +161723*****
What schools did Rami Rahal attend?
Rami Rahal attended Massachusetts Institute Of Technology, Mcmaster University.
What skills is Rami Rahal known for?
Rami Rahal has skills like Cell Biology, Genetics, Genomics, Molecular Biology, Oncology, Biochemistry, Signal Transduction, Dna Sequencing, Biomarkers, Drug Discovery, Cell Culture, High Throughput Screening.
Who are Rami Rahal's colleagues?
Rami Rahal's colleagues are Elizabeth Stoner, Mr.mohinder Singh, Elmo Girao, Vaughn Kailian, Karim Choulak, Arul Afif, Mazur Ryszard.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial